Venture Life Group plc

VLG

GB00BFPM8908

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:18 2024-07-17 am EDT			5-day change	1st Jan Change
49 ^GBX	+1.03%		+8.89%	+46.27%

Jun. 04	Venture Life confident in outlook for year; performs in line	AN
Apr. 19	Venture Life renews revolving credit facility with Santander and HSBC	AN

Venture Life Group plc Announces Revenue Results for the Year Ended December 31, 2016

January 26, 2017 at 02:00 am EST

Venture Life Group Plc announced revenue results for the year ended December 31, 2016. The Group has achieved record revenue for the year ended 31 December 2016 of £14.3 million, an increase of 57% on reported Group revenue for the prior year.

Latest news about Venture Life Group plc

Venture Life confident in outlook for year; performs in line	Jun. 04	AN
Venture Life renews revolving credit facility with Santander and HSBC	Apr. 19	AN
Venture Life Group plc Renews Revolving Credit Facility with Santander UK PLC and HSBC Innovation Bank Limited	Apr. 19	CI
Jaguar Health Licenses Fda-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in Its Core Focus Area of Cancer Supportive Care	Apr. 16	CI
Venture Life to benefit from higher prices as profit surges in 2023	Apr. 09	AN
Earnings Flash (VLG.L) VENTURE LIFE GROUP Reports FY23 Revenue GBP51.4M	Apr. 09	MT
Earnings Flash (VLG.L) VENTURE LIFE GROUP Reports FY23 EPS GBX0.68	Apr. 09	MT
Venture Life Group plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Venture Life credits success to portfolio "robustness and variety"	Feb. 01	AN
Venture Life loss widens on higher amortisation and finance costs	23-09-25	AN
Earnings Flash (VLG.L) VENTURE LIFE GROUP Posts H1 Revenue GBP23.5M	23-09-25	MT
Earnings Flash (VLG.L) VENTURE LIFE GROUP Reports H1 Loss GBX-1.19	23-09-25	MT
Venture Life Group plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-25	CI
Stocks called lower amid trouble in China	23-09-25	AN
FTSE 100 Reaches Two-Month High Lifted by Miners, Oil-Exposed Stocks	23-07-31	DJ
Venture Life interim revenue rises, outlook remains hopeful	23-07-31	AN
Venture Life Group plc Reports Revenue Results for the Six Months Ended 30 June 2023	23-07-31	CI
Venture Life sees minor shareholder rebellion at AGM	23-05-22	AN
FTSE 100 Closes Up 0.2% Lifted by Banks, Discretionary Sector	23-05-22	DJ
UK Labor Market Loosening Suggests Peak Interest Rates Are Near	23-05-22	DJ
Venture Life eyes annual performance in line with guidance	23-05-22	AN
BOE Could Increase Pace of Quantitative Tightening, Still Cut Rates in 2024	23-05-22	DJ
FTSE 100 Rises Amid Optimism Over Improved US-China Relations	23-05-22	DJ
Sterling Could Rise if UK Underlying Price Pressures Persist	23-05-22	DJ
Venture Life Co-Founder & CCO Sharon Daly steps down	23-05-19	AN

Chart Venture Life Group plc

Duration

Period

More charts

Company Profile

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The principal activities of the Company are the development, manufacturing, and commercialization of healthcare products, including medical devices, food supplements and cosmetics for the ageing population. The Company's product portfolio includes products, such as the UltraDEX and Dentyl oral care product ranges; the Balance Activ range in the area of women's intimate healthcare; the Lift Glucose and Glucogel product ranges for hypoglycaemia; Gelclair, Xonrid, and Pomi-T for oncology support products provide symptomatic relief for some of the side effects associated with cancer and its treatment; the Procto-eze Plus product ranges for hemorrhoids, and other Dermatology products. The Company operates through two segments: Venture Life Brands and Customer Brands. The Company's subsidiaries include Venture Life Limited, Lubatti Limited, Periproducts Limited, HL Healthcare Ltd, and Venture Life Healthcare Ltd.

Sector

Pharmaceuticals

Calendar

2024-09-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Venture Life Group plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VENTURE LIFE GROUP PLC	+46.27%	79.58M
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals